Marco Gobbi

Years Active: 2020-2022
Publications (10 Years): 2

This page only lists publications with an associated author ORCID identifier.

Publications

Amer M Zeidan, Pierre Fenaux, Marco Gobbi, Jiří Mayer, Gail J Roboz, Jürgen Krauter, Tadeusz Robak, Hagop M Kantarjian, Jan Novák, Wieslaw Wiktor Jedrzejczak, Xavier Thomas, Mario Ojeda-Uribe, Yasushi Miyazaki, Yoo Hong Min, Su-Peng Yeh, Joseph M Brandwein, Liana Gercheva, Judit Demeter, Elizabeth A Griffiths, Karen W L Yee, Jean-Pierre J Issa, Jan Philipp Bewersdorf, Harold Keer, Yong Hao, Mohammad Azab, Hartmut Döhner
Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy. Blood 140 (3) (2022)
Paola Minetto, Anna Candoni, Fabio Guolo, Marino Clavio, Maria Elena Zannier, Maurizio Miglino, Maria Vittoria Dubbini, Enrico Carminati, Anna Sicuranza, Sara Ciofini, Nicoletta Colombo, Girolamo Pugliese, Riccardo Marcolin, Adele Santoni, Filippo Ballerini, Luca Lanino, Michele Cea, Marco Gobbi, Monica Bocchia, Renato Fanin, Roberto Massimo Lemoli
Fludarabine, High-Dose Cytarabine and Idarubicin-Based Induction May Overcome the Negative Prognostic Impact of FLT3-ITD in NPM1 Mutated AML, Irrespectively of FLT3-ITD Allelic Burden. Cancers 13 (1) (2020)

Marco Gobbi.css-eqlu8i{font-size:small;padding-left:4px;}